Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.75 |
| ▸ | STK10 | O94804 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | RET | P07949 | 2/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.75 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | CSF1R | P07333 | 1/20 | 0.75 |
| ▸ | HCK | P08631 | 1/20 | 0.75 |
| ▸ | KIT | P10721 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226302 | 0.88 | KDR (0.81) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL18319844 | 0.88 | KDR (0.73) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227589 | 0.86 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227112 | 0.86 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227111 | 0.86 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL29354510 | 0.86 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL2263523 | 0.85 | CYP3A4 (0.76) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL17377930 | 0.85 | CYP3A4 (0.76) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL28521461 | 0.84 | CYP3A4 (0.66) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL28521459 | 0.84 | CYP3A4 (0.66) | KDRCYP3A4FGFR1KCNH2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| US-10736900-B2 | Combinations of an FGFR inhibitor and an IGF1R inhibitor | ASTEX THERAPEUTICS LTD (GB) | 2020-08-11 | — | — | US | disclosed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736900-B2 | Combinations of an FGFR inhibitor and an IGF1R inhibitor | IGF1R, FGFR3, FGFR1 | KDR 37/4885CYP3A4 3346/4885FGFR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.